|
|
News Breaks | | | | September 5, 2012 | | 08:57 EDT |  | TRGT | Targacept to develop TC-5214 for overactive bladder
Targacept plans to pursue development of TC-5214 as a treatment for overactive bladder. Based on TC-5214’s unique pharmacokinetic profile, an analysis of data from a completed clinical program and findings from additional preclinical studies, the company plans to initiate a Phase 2b study of TC-5214 in 1H2013. | |
|
News For TRGT From The Last 14 Days Check below for free stories on TRGT the last two weeks. |
|
|
| May 7, 2013 | | 07:41 EDT |  | TRGT | Targacept reports Q1 EPS (24c), consensus (34c)
Reports Q1 revenue $3.5M, consensus $600,000. | |
|
|
|
|
|
|
